GlassScriptPhysician profile
John L Winkelman
NPI 1093804163
$1,588.71
in general payments reported to CMS, 2019-2025
32 companies · $148 in 2025
The $148 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $144 · 2021: $242 · 2022: $422 · 2023: $140 · 2024: $291 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $176.93 | 2019-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $176.67 | 2020-2023 | Gardasil 9, Vaxneuvance, Rotateq |
| Abbvie INC. | $132.37 | 2021-2022 | |
| Pfizer INC. | $115.11 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.59 | 2021-2022 | |
| Glaxosmithkline, LLC. | $73.49 | 2019-2024 | Bexsero |
| Exact Sciences Corporation | $69.33 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $56.42 | 2019-2024 | Farxiga |
| Gilead Sciences, INC. | $47.58 | 2019 | |
| Lilly USA, LLC | $43.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.11 | 2022 | |
| Ironshore Pharmaceuticals INC. | $36.88 | 2024 | |
| Sanofi-Aventis U.S. LLC | $34.84 | 2020-2022 | |
| Alk-Abello, INC | $32.38 | 2025 | Odactra, Ragwitek, Grastek |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.08 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.16 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $26.41 | 2024 | Injectafer |
| Sanofi Pasteur INC. | $25.92 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $25.69 | 2021 | |
| Viatris Specialty LLC | $24.05 | 2025 | Yupelri |
| Evofem Biosciences, INC. | $23.51 | 2021 | |
| Mylan INC. | $21.85 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.19 | 2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $20.00 | 2019 | |
| Coopersurgical, INC. | $19.60 | 2025 | Paragard T 380a |
| Neurocrine Biosciences, INC. | $19.23 | 2025 | |
| Sage Therapeutics, LLC | $17.01 | 2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2019 | |
| Amarin Pharma, INC. | $15.54 | 2021 | |
| Therapeuticsmd, INC. | $14.87 | 2021 | |
| Roche Diagnostics Corporation | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Winkelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.